Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: The FUSIDM trial

Diabetologia

Volumn 48, Issue 8, 2005, Pages 1464-1468

  Conget, I ^a   Aguilera, E ^a   Pellitero, S ^a   Naf S ^a   Bendtzen, K ^b   Casamitjana, R ^a   Gomis, R ^a   Nicoletti, F ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Fusidin; Immunotherapy; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; FUSIDATE SODIUM; GLUCAGON; INSULIN; INSULIN ANTIBODY; PLACEBO;

ADULT; ANTIBODY TITER; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FUSIDIC ACID; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; INSULIN; ISLETS OF LANGERHANS; MALE;

EID: 23844521951     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-1823-2     Document Type: Article

References (21)

1. Winter WE, Schatz D (2003) Prevention strategies for type 1 diabetes mellitus. Biodrugs 17:39-64
2. Nicoletti F, Moroni PL, Benetzen K (1996) Fusidic acid and insulin-dependent diabetes mellitus. Autoimmunity 24:187-197
3. Bendtzen K, Diamant M, Faber V (1990) Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine 2:423-429
4. Nicoletti F, Zaccone P, Di Marco R et al (1995) Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 85:645-650
5. Nicoletti F, Di Marco R, Morrone S et al (1994) Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats treated with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-γ. Immunology 81:317-321
6. Hageman I, Buschard K (2002) Antidiabetogenic effect of fusidic acid in diabetes prone BB rats: a sex-dependent organ accumulation of the drug is seen. Pharmacol Toxicol 91:123-128
7. Nicoletti F, Di Marco R, Conget I et al (2000) Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. J Autoimmun 15:395-405
8. Nicoletti F, Meroni PL, Lunetta M et al (1991) Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet 337:1292
9. Nicoletti F, Nicoletti A, Giuffrida S et al (1998) Sodium fusidate in Guillain Barré syndrome: a case report. J Neurol Neurosurg Psychiatry 65:266-268
10. Nicoletti F, Patti F, Nicoletti A et al (1999) Sodium fusidate in steroid resistant relapses of multiple sclerosis. Mult Scler 5:377
11. Vidal J, Fernandez Balsells M, Sesmilo G et al (2000) Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 23:360-364
12. Greenbaum C, Harrison LC (2003) Guideleines for interventions trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52:1059-1065
13. Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698
14. Raz I, Elias D, Avron A et al (2001) Beta-cell function in new onset type 1 diabetes and immimomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358:1749-1753
15. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C (2001) Effects of strict blood glucose control on residual beta-cell function in insulin dependent diabetics. Diabetologia 20:530-534
16. The Diabetes Control and Complications Trial Research Group (1988) Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 128:517-523
17. Mori Y, Suko M, Okudaira H et al (1986) Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 29:244-247
18. Like AA, Dirodi V, Thomas S, Guberski DL, Rossini AA (1984) Prevention of diabetes mellitus in the BB/W rat with cyclosporin-A. Am J Pathol 117:92-97
19. Sestier C, Odent-Pogu S, Bonneville M, Maurel C, Lang F, Sai P (1985) Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett 10:57-60
20. Roep BO, Atkinson M (2004) Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 47:1650-1656
21. Roep BO, Atkinson M, von Herrath M (2004) Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4:989-997